Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 939-942

  Breuer, T ^a   Kim, J G ^b   El Zimaity, H M T ^a   Nikajima, S ^a   Ota, H ^a   Osato, M ^a   Graham, D Y ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Korea University College of Medicine   (South Korea)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; NIZATIDINE; ANTIINFECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PENICILLIN DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BREATH ANALYSIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DUODENUM ULCER; ENDOSCOPY; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RASH; SMOKING; STOMACH ULCER; XEROSTOMIA; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; HELICOBACTER INFECTION; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; KOREA; MALE; MIDDLE AGED; NIZATIDINE; PENICILLINS; PEPTIC ULCER;

EID: 0031252351     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00233.x     Document Type: Article

References (32)

1. Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 1991; 6: 105-13.
2. Dixon MF. Helicobacter pylori and peptic ulceration: histopathological aspects. J Gastroenterol Hepatol 1991; 6: 125-30.
3. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. J Am Med Assoc 1994; 272: 65-9.
4. van der Hulst RWM, Keller JJ, Rauws EA, Tytgat GNJ. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter 1996; 1: 6-19.
5. Labenz J, Gyenes E, Ruhl GH, Borsch G. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 1993; 34: 1167-70.
6. Labenz J, Gyenes E, Rühl GH, Börsch G. Omeprazole plus amoxicillin: Efficacy of various treatment regimen to eradicate Helicobacter pylori. Am J Gastroenterol 1993; 88: 491-5.
7. Bayerdörffer E, Mannes GA, Sommer A, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4: 697-702.
8. Graham KS, Malaty H, El-Zimaity HM, et al. Variability with omeprazoleamoxicillin combinations for treatment of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 1415-8.
9. van der Hulst RW, Weel JF, Verheul SB. et al. Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. Aliment Pharmacol Ther 1996; 10: 165-71.
10. Gisbert JP, Mur M, Sainz S, et al. Is the omeprazole and amoxicillin combination useful in the treatment eradicating Helicobacter pylori in Spain? Rev Esp Enferm Dig 1996; 88: 99-106.
11. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12.
12. Al-Assi MT, Genta RM, Karttunen TJ, Graham DY. Clarithromycin amoxycillin therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8: 453-6.
13. Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994; 25: 221-6.
14. Hachem CY, Clarridgc JE, Reddy R, et al. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-Test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis 1996; 24: 37-41.
15. Fagan T. Quickbasic program for exact and mid-P confidence intervals for binomial proportion. Biol Med 1996; 26: 263-7.
16. Peura DA, Graham DY. Helicobacter pylori: consensus reached: peplic ulcer is on the way to becoming an historic disease. Am J Gastroenterol 1994; 89: 1137-9.
17. Börsch GM, Graham DY. Helicobacter pylori. In: Collen MJ, Benjamin SB, eds. Pharmacology of Peptic Ulcer Disease Handbook of Experimental Pharmacology, Vol. 99. Berlin: Springer, 1991: 107-48.
18. Penston JG. Review article: Helicobacter pylori eradication understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994; 8: 369-89.
19. Graham DY. Determinants of antimicrobial effectiveness in H. pylori gastritis. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure. Dordrecht: Kluwer Academic, 1994: 531-7.
20. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
21. Graham DY. A reliable cure for Helicobacter pylori infection? Gut 1995; 37: 154-6.
22. Logan RPH, Gummett PA, Thomas P, et al. The dose and frequency of omeprazole influence the eradication rate of dual therapy. Acta Gastroenterol Belg 1993; 56: 140.
23. Savarino V, Sandro Mela G, Zentilin P, Vigneri S, Celle G. Acid inhibition and amoxicillin activity against Helicobacter pylori. Am J Gastroenterol 1993; 88: 1975-6.
24. Hunt RH. pH and Hp - gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993; 88: 481-5.
25. Axon AT. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994; 201(Suppl.): 16-23.
26. Malanoski GJ, Eliopoulos GM, Ferraro MJ, Moellering RCJ. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temalloxacin. Eur J Clin Microbiol Infect Dis 1993; 12: 131-3.
27. Graham DY, Genta RM, Evans DG. et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol 1997; 91: 2120-4.
28. Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 1029-33.
29. Yousli MM, El-Zimaity HMT, Genta RM, Graham DY. One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 617-21.
30. Versalovic J, Shortridge D, Kibler K. et al. Mutations in 23 rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-80.
31. Megraud F. What is the relevance of resistance of Helicobacter pylori to antimicrobial agents? In: Hunt RH, Tytgat GNJ. eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure 1996. Dordrecht: Kluwer Academic, 1997: 348-56.
32. Breuer T, Kim JG, Gurer IE, et al. Successful low dose amoxicillin. metronidazole. omeprazole combination therapy in a population with a high frequency of metronidazole resistant H. pylori. Aliment Pharmacol Ther 1997; 11: 523-527.